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Chlamydia trachomatis is considered the most common bacteria causing genital infections in the industrialised world. In women, the infection may lead to serious complications such as pelvic inflammatory disease (PID) with consequences including infertility, ectopic pregnancy, and chronic pelvic pain. It For LCR, a co-amplification for the simultaneous detection of Neisseria gonorrhoeae from the same specimen has been developed and is already commercially available, although processing is done separately in the laboratory for both bacteria. The most recent development of amplification tests is the Gen-Probe amplified Chlamydia trachomatis assay which is a transcription mediated amplification (TMA) with the ribosomal RNA as the target to be amplified and detected. The TMA uses two primers, one containing a promoter sequence for the RNA polymerase and a second primer binding to a DNA copy. One of the two enzymes, the reverse transcriptase creates a DNA copy of the target rRNA by extension from the 3' end of the promoter primer. The second enzyme, the RNA polymerase, recognises the promoter sequence in the DNA template and initiates transcription. Each of the DNA templates can make 100-1000 copies of RNA amplicon, resulting in a production of 10 billion amplicons in less than one hour. Detection of these amplicons occurs by the same hybridisation protection assay (HPA) which utilises a highly sensitive chemiluminescent signal as in the PACE 2 assay. One of the advantages of the TMA is the high number of rRNAs in each infected cell. Furthermore, the test procedure is simple to perform, the TMA is an isothermal process and does not require a thermocycler for the amplification step.
For amplification tests transport and storage conditions are less critical when compared with culture. Transport media are usually provided by the manufacturer. Although processing of the test requires precautions against contamination, the performance is already partly automated, and reading is objective and simple. The The evaluation of amplification tests started with comparison studies of genital samples using either cervical or urethral swabs from men and women. Because of the high sensitivity of amplifying tests the results are less dependent on the quality of specimens and an inadequately collected or transported specimen with a low number of infectious agents can be dealt with.
NON-INVASIVE SAMPLES
In contrast with genital samples, non-invasive specimens such as urine and introital smears from the vulval region are easy to collect, giving access to a large population group, and so are important for screening adolescents with a high prevalence of asymptomatic chlamydial infections. Indeed, since in some women chlamydia can only be isolated from urethral samples, these tests may have higher detection rates through contamination from urethral and cervical specimens than samples taken from the cervix alone.
Since most of the organisms contaminating urine are no longer viable, urine as a non-invasive specimen is not an appropriate sample for chlamydial diagnosis by cell culture, as it gives a low sensitivity of up to 30% from urine samples.'3 Furthermore, vulval smears obtained from the introitus vulvae should not be used to perform cell culture. In a comparative study using vulval specimens in addition to urine and cervical swabs the sensitivity of culture on vulval swabs was only 22.2%, similar to the data for urine. '4 Antigen detection tests were not only evaluated for invasive but also for non-invasive samples, especially in men, suggesting a role of urine as screening tool.' [1] [2] [3] [4] [5] [6] [7] [8] Chlamydial diagnosis on the deposit of centrifuged first void urine (FVU) has been performed with different EIAs mostly in men. The first results of urine testing looked promising when compared with culture, with a sensitivity of about 80% to 85% for the Chlamydiazyme and the EIA Baxter Bartels on male urine sediment in asymptomatic and symptomatic men.'718 The problem at that time was that calculations were performed with culture as the gold standard for the specificity as well as sensitivity of EIAs on urine sediment. These enthusiastic first data reported in some studies had to be revised by the newly introduced amplifying techniques, which have shown a poor sensitivity for culture as well as for the EIA on urine especially in asymptomatic individuals, with a sensitivity not higher than 40%. '9 Although the diagnosis of EBs in the urine sediment by the DFA gave a better result for sensitivity and specificity than did EIAs, the disadvantage of the DFA on urine sediment is the labour intensive procedure and dependence on the expertise of the observer. Thus, it is not suitable for the performance of screening programmes in a larger population group.
Amplifying assays are highly effective in identifying genital chlamydial infections in men and in women not only by testing invasive samples but also by using FVU as a non-invasive specimen." [20] [21] [22] Automated LCR assay on FVU of about 2000 women detected up to 30% more infected women than did endocervical swab culture.2' So far, the LCR assay is highly effective for the detection of C trachomatis even in urine of females with or without signs or symptoms of a genital chlamydial infection. Similar to LCR, testing urine sediment with the commercially available PCR Amplicor (Roche Diagnostic Systems, Branchburg, NJ, USA) performs with a higher sensitivity when compared with urethral and cervical culture."1 23 In a study on 415 women, culture detected 61.2% of infected women compared with 87-8% for the commercial PCR assay Amplicor on urine." Using the Amplicor for testing urine in 713 men the sensitivity of culture on urethral specimens was only 50.7% and the resolved sensitivity of Amplicor on urine was 88%, confirming that this technique provides a non-invasive diagnostic assay for routine screening for chlamydial infection.
Since in asymptomatic individuals only a small amount of infectious agents can be expected, detection of micro-organisms requires the use of nucleic acid amplification. This was shown in a recently performed comparative study in 705 asymptomatic male recruits.'9 We compared the performance of two different amplification assays, the LCR and PCR, with that of the EIA and FVU. The results confirm that both amplification methods were similarly sensitive (93 1%) using frozen urine of asymptomatic young men, which the EIA performed with a poor sensitivity of 37.9% and cannot be recommended as a suitable alternative test for urine, especially of asymptomatic men.
Recently, we investigated whether vulval specimens as an alternative non-invasive specimen in women may also be suitable for chlamydial diagnosis.'4 In this study LCR, culture, and EIA were tested on different specimens from various sampling sites in women, including vulval smears and FVU as well as swabs from the endocervical canal and the urethra. The principal question was whether the vulval region may act as an alternative noninvasive sampling site which could substitute FVU for the detection of C trachomatis in women. Whereas LCR showed a high sensitivity for all specimen types (85-2% for vulval, urine, and endocervical specimens, each), the sensitivity of culture and EIA was high only with endocervical swabs (74. 1% and 70.4%, respectively), and low for vulval specimens (22-2% and 40.7%). The high sensitivity for vulval and urine specimens using LCR was confirmed by a further study in 312 women, and seems not to be influenced by either the viability of the organism or by the low number of infectious particles. It can be explained as a result of the ability of this technology to amplify even a small amount of chlamydial DNA. Furthermore, it confirms the presence of EBs in the vulval region contaminated from the cervical and urethral region, similar to urine swabs. The low sensitivity of vulval swabs by culture is most probably the result of the low number of viable organisms as is the case with urine samples. The low sensitivity of the EIA when testing vulval swabs may be due to the low number of EBs in the specimens, below the detection limit of this technique. Vulval specimens as with FVU, seem not to be suitable for chlamydial diagnosis by culture 
